Drug Profile
Research programme: cancer therapeutics - Bayer HealthCare Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Germany
- 17 May 2011 Celera Corporation has been acquired by Quest Diagnostics
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals